MAGEA3 and melanoma: Similarly, expression of CXCR2 in transgenic pmel-1 or MAGE-A3 T-cell receptor-engineered T-cells enhanced their ability to migrate to subcutaneous xenografts of melanoma and colonic origin [55,56].